Genetech’s new multiple sclerosis treatment, called Ocrevus, is the first drug approved for treating primary progressive MS. It can also treat relapsing MS, which is the more common version of the disease.
Prescriptions of this new drug are soaring, according to the Boston Globe. Ocrevus works by targeting B-cells, which is a new approach to MS therapy.
